AC
NVO

AlphaCore Capital’s Novo Nordisk NVO Stock Holding History

AlphaCore Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$287K Buy
5,981
+624
+12% +$26.8K 0.01% 941
2026
Q1 		$203K Sell
5,357
-5,246
-49% -$249K ﹤0.01% 841
2025
Q4 		$539K Sell
10,603
-9,427
-47% -$482K 0.01% 590
2025
Q3 		$1.11M Buy
20,030
+1,081
+6% +$63.3K 0.04% 279
2025
Q2 		$1.31M Buy
+18,949
New +$1.29M 0.05% 222

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

AlphaCore Capital's NVO Position: Q2 2026 in Review

AlphaCore Capital increased its Novo Nordisk (NVO) stake by 12% in Q2 2026, buying an estimated $26.8K and bringing the position to 5,981 shares worth $287K. The position accounts for 0.01% of the portfolio, ranked #941.

AlphaCore Capital first reported a position in NVO in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.31M in Q2 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • AlphaCore Capital held 5,981 shares of Novo Nordisk worth $287K as of Q2 2026.
  • AlphaCore Capital bought 624 Novo Nordisk shares in Q2 2026, an estimated $26.8K.
  • Novo Nordisk made up 0.01% of AlphaCore Capital's portfolio in Q2 2026, its #941 holding.
  • AlphaCore Capital first reported a position in Novo Nordisk in Q2 2025 and has held it in 5 quarters since.
  • AlphaCore Capital's Novo Nordisk position peaked at $1.31M in Q2 2025.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.